Target to $32 from $40
Friday, July 12, 2019
MediciNova readies late-stage study of MN-166 in progressive MS
Subsequent to FDA feedback, MediciNova (NASDAQ:MNOV) has finalized the protocol for a Phase 3 clinical trial evaluating MN-166 (ibudilast) in patients with secondary progressive multiple sclerosis (MS) without relapses.
The primary endpoint will be the time to three-month confirmed disability progression as measured by a scale called EDSS, the same endpoint used for other drugs approved for progressive MS.
The agency indicated that one study may be sufficient to support a marketing application.
The size of the study and its projected start date are not provided.
Subscribe to:
Posts (Atom)